Roberts Glore & Co. Inc. IL Invests $648,000 in Biogen Inc. $BIIB

Roberts Glore & Co. Inc. IL acquired a new stake in shares of Biogen Inc. (NASDAQ:BIIB) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 3,001 shares of the biotechnology company’s stock, valued at approximately $648,000.

A number of other large investors have also bought and sold shares of the business. BlackRock Inc. acquired a new stake in Biogen during the 2nd quarter worth approximately $3,453,878,000. Primecap Management Co. CA bought a new stake in shares of Biogen during the second quarter worth $3,274,304,000. Norges Bank acquired a new stake in shares of Biogen during the fourth quarter worth $464,408,000. Boston Partners bought a new stake in Biogen in the 4th quarter valued at $302,815,000. Finally, Legal & General Group Plc bought a new stake in Biogen in the 2nd quarter valued at $322,640,000. 87.93% of the stock is owned by institutional investors.

Biogen Price Performance

NASDAQ:BIIB opened at $220.77 on Wednesday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87. The stock’s 50-day simple moving average is $206.42 and its 200 day simple moving average is $195.12. The company has a market cap of $32.62 billion, a P/E ratio of 39.07, a P/E/G ratio of 6.80 and a beta of 0.17. Biogen Inc. has a 52-week low of $131.52 and a 52-week high of $222.85.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The business had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. During the same quarter in the prior year, the company posted $5.47 earnings per share. Biogen’s revenue was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, sell-side analysts forecast that Biogen Inc. will post 12.39 EPS for the current fiscal year.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: LEQEMBI IQLIK launches in the U.S.: Biogen and Eisai announced that the once-weekly subcutaneous autoinjector is now available to initiate treatment for adults with early Alzheimer’s disease. The option can be administered at home, potentially reducing clinic visits, improving treatment convenience and expanding adoption of LEQEMBI. LEQEMBI IQLIK Autoinjector Available in the U.S.
• Positive Sentiment: Potential commercial benefit: LEQEMBI IQLIK offers flexibility between intravenous and subcutaneous dosing for both initiation and maintenance therapy. Easier administration could lower barriers for patients and caregivers and support longer-term revenue growth from Biogen’s Alzheimer’s partnership with Eisai. The drug has demonstrated a 27% slowing of cognitive decline versus placebo in the pivotal study, although Biogen shares commercialization with Eisai.
• Positive Sentiment: Fundamental and institutional support: Biogen’s latest reported quarter included adjusted EPS of $3.60 and revenue of $2.74 billion, both ahead of expectations. Recent data also indicate more institutional investors increased positions than reduced them, while several analysts maintain Buy or Outperform ratings and a median price target around $225.
• Neutral Sentiment: Short-interest report appears unreliable: The data lists zero shares sold short both before and after the reporting period, making the stated “large increase” and NaN percentage mathematically meaningless. It provides no credible evidence of a short squeeze or materially changed investor positioning.
• Negative Sentiment: Bearish valuation commentary: A recent analysis titled “3 Reasons to Sell BIIB” argues that the shares’ roughly 14.4% six-month gain has largely followed the broader market, raising questions about additional upside and relative attractiveness. The article’s bearish view could limit enthusiasm after the recent rally. 3 Reasons to Sell BIIB and 1 Stock to Buy Instead
• Negative Sentiment: LEQEMBI safety risks remain: The treatment carries a boxed warning for amyloid-related imaging abnormalities, including potentially serious brain swelling and hemorrhage. These risks, along with required MRI monitoring and higher ARIA incidence among ApoE ε4 homozygotes, could constrain uptake and increase implementation costs.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. TD Cowen increased their target price on Biogen from $215.00 to $225.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Needham & Company LLC upped their price objective on Biogen from $255.00 to $256.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Royal Bank Of Canada increased their price objective on Biogen from $240.00 to $260.00 and gave the stock an “outperform” rating in a report on Tuesday. Wall Street Zen lowered Biogen from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Citigroup upped their price target on Biogen from $200.00 to $215.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $227.79.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.